CLINICAL AND PARACLINICAL CHARACTERISTICS OF PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDERS
Main Article Content
Abstract
Objectives: To describe the clinical and paraclinical characteristics of neuromyelitis optica spectrum disorders (NMOSD). Methods: A prospective, descriptive study was conducted on 43 patients treated at the Neurology Department of 108 Military Central Hospital diagnosed with NMOSD according to the 2015 IPND criteria. Results: The disease predominantly affected females (93.4%), with a female-to-male ratio of approximately 20:1. The average onset age was 44.2 ± 13.9 years. The disease showed immune overlap phenomena. Most active episodes presented with a single clinical syndrome. During active disease episodes, acute myelitis and optic neuritis were the most common clinical syndromes,, accounting for 80.5% and 28.3%, respectively; area postrema syndrome 8.8% and acute brainstem syndrome 10.1%. The relapse rate was high, with 65.8% in the first year and 89.6% in the first five years. 90% of patients were positive for anti-AQP4 antibodies, all of whom were female. CSF analysis showed increased CSF protein in 67.9% and increased white blood cells in 37%. MRI findings indicated long-segment myelitis and optic neuritis. Conclusion: The disease is common in females under 50, has a high relapse rate, and most patients are positive for anti-AQP4 antibodies. Clinical findings often include longitudinal extensive tranverse myelitis and optic neuritis, with additional brainstem involvement.
Article Details
Keywords
Neuromyelitis optica spectrum disorders, AQP4, longitudinal extensive tranverse myelitis
References
2. Cree BA and SL Hauser. Neuromyelitis Optica, in Harrison's Principles of Internal Medicine. 20th, Mc Graw Hll Education, Editor; 2018, chapter 437.
3. Wingerchuk DM, B Banwell, JL Bennett, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-189.
4. Papp V, M Magyari, O Aktas, et al. Worldwide Incidence and prevalence of neuromyelitis optica: A systematic review. Neurology. 2021; 96(2):59-77.
5. Shahmohammadi S, R Doosti, A Shahmohammadi, et al. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019; 27:350-363.
6. Liu C, M Shi, M Zhu, et al. Comparisons of clinical phenotype, radiological and laboratory features, and therapy of neuromyelitis optica spectrum disorder by regions: Update and challenges. Autoimmun Rev. 2022; 21(1):102921.
7. Weihe Zhang, Lei Cui, Yeqiong Zhang, et al. Questioning the existence of monophasic neuromyelitis optica spectrum disorder by defining a novel long term relapse free form from a large Chinese population. Journal of Neurology. 2020; 267:1197-1205.
8. Sellner J, M Boggild, M Clanet, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17(8):1019-1032.